CORE--CLINICAL

描述：该项目的主干是临床站点核心 它统一了提案的总体目标：1)隔离、表征、 并合成母乳中的生物活性物质(包括 糖偶联物、抗体和抗炎因子)保护 婴儿肠道病原体；2)通过分子流行病学评估 研究，保护母乳喂养的婴儿免受肠道病原体的侵袭；3) 通过随机试验确定特定生物活性物质的疗效 母乳中可保护婴儿免受肠道感染的物质 感染和疾病；以及4)确定母乳对 对肠道病原体和疫苗的免疫反应的调节。 在上一次申请的前一个资助期，临床网站 CORE支持所有项目。这包括共享人口统计数据。 和标本，在墨西哥进行实地研究(圣佩德罗马蒂尔，特拉尔潘) 和诺福克，来自墨西哥和美国母亲的标本收集，以及 生化和生物统计学方面的支持。始于1987年的田野调查 墨西哥已经招收了600多名婴儿和400名母亲。其他内容 研究(非该项目资助)在诺福克招募了600多名婴儿。 核心维护了一个所有生物样本的数据库，由 所有调查人员。已经有超过2800份牛奶，1600份血液和3.2万份 收集的粪便样本，其中大部分已被耗尽，用于在 1993-2008年期间的具体项目。剩下的一些粪便样本可以 用于拟议的项目，但血液和牛奶仍然太少 需要样本和/或附加样本，以满足 目前的建议。

Description: The backbone of this program project is the Clinical Site Core which unites the overall aims of the proposal: 1) to isolate, characterize, and synthesize the bioactive substances in human milk (including glycoconjugates, antibodies, and anti-inflammatory factors) that protect the infant from enteropathogens; 2) to evaluate, through molecular-epidemiologic research, the protection of breast-fed infants from enteropathogens; 3) to determine, through randomized trials, the efficacy of specific bioactive substances identified in human milk to protect the infant from enteric infection and disease; and 4) to determine the effect of human milk on modulation of the immune response to enteric pathogens and vaccines. In the previous funding period of the previous application, the Clinical Site Core supported all projects. This included the sharing of demographic data and specimens, conducting field studies in Mexico (San Pedro Martir, Tlalpan) and Norfolk, specimen collection from Mexican and U.S. mothers, as well as biochemical, and biostatistical support. Field studies originating in 1987 in Mexico have enrolled in excess of 600 infants and 400 mothers. Additional studies (funded outside this project) enrolled over 600 infants in Norfolk. The Core maintained a database of all biological samples which was shared by all investigators. There have been over 2,800 milk, 1,600 blood, and 32,000 fecal samples collected, much of which has been depleted for analyses in the specific projects during 1993-8. Some of the remaining fecal samples can be used for the proposed projects, but there remain too few blood and milk samples and/or additional samples are needed to address newer aims in the current proposal.